{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-086088","form_type":"8-K","ticker":"PTGX","cik":"0001377121","company_name":"Protagonist Therapeutics, Inc","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.833914+00:00","generated_at":"2026-05-31T12:12:19.874261+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Protagonist Q2 net loss $30.6M; cash $595.4M; JNJ-2113 Phase 3 data expected Q4 2024","bullets":["Q2 net loss of $30.6M ($0.50/share) vs $38.5M loss in Q2 2023; six-month net income $176.7M from Takeda upfront.","Cash, equivalents and marketable securities of $595.4M as of June 30, 2024; runway through end of 2027.","JNJ-2113 Phase 3 ICONIC-LEAD and ICONIC-TOTAL in psoriasis primary endpoint completion expected Q4 2024.","Phase 2b ANTHEM in ulcerative colitis primary endpoint completion also expected Q4 2024; Phase 3 VERIFY rusfertide topline due Q1 2025.","Dr. Newman Yeilding appointed Chief Scientific Advisor effective August 1, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-086088","json":"https://secwatch.observer/filing/0001104659-24-086088.json","markdown":"https://secwatch.observer/filing/0001104659-24-086088.md","text":"https://secwatch.observer/filing/0001104659-24-086088.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924086088/0001104659-24-086088-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924086088/tm2419327d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:12:19.874261+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}